Q fever vaccine development: Challenges and progress in balancing safety and efficacy

Ann E Sluder; Mark C Poznansky

doi:10.1016/j.xcrm.2021.100480

Q fever vaccine development: Challenges and progress in balancing safety and efficacy

Cell Rep Med. 2021 Dec 21;2(12):100480. doi: 10.1016/j.xcrm.2021.100480.

Authors

Ann E Sluder¹, Mark C Poznansky¹

Affiliation

¹ Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA.

Abstract

The existing human vaccine against Q fever, a zoonotic disease of biothreat concern, is approved only in Australia. In this issue of Cell Reports Medicine, Gregory and colleagues describe a new vaccine candidate that overcomes specific concerns hindering wider acceptance of the commercial vaccine.¹.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Animals
Australia
Bacterial Vaccines
Humans
Q Fever* / prevention & control
Vaccination
Zoonoses

Substances

Bacterial Vaccines